PhRMA campaign touts Part D positives

Share this article:
PhRMA campaign touts Part D positives
PhRMA campaign touts Part D positives
PhRMA launched a national TV ad campaign aimed in part at dissuading congressional Democrats from tampering with the Medicare Part D prescription drug benefit to allow the government to negotiate drug prices.

The ad celebrates the successes of Medicare Part D, and asks viewers to call 202-224-3121 and “tell Congress we need quality affordable healthcare coverage for every American.”

“All across America, over 26 million seniors have signed up for Medicare drug coverage, choosing a private plan that fits their needs, and saving an average of $1,200.00 a year on their prescription medicine,” says the ad's narrator. “And with competition holding down costs, taxpayers are saving billions. The Medicare benefit is working, and seniors are happy.”

According to a PhRMA release, the campaign touts “the importance and success of free-market initiatives such as [Medicare Part D].” The “free-market” elements of Medicare Part D – in particular, a policy provision barring Medicare from negotiating drug prices with manufacturers – have been challenged anew by congressional Democrats.

Two bills introduced in Congress last January, one in the House (H.R.684) and one in Senate (S.330), by Rep. Robert Berry (D-AR) and Sen. Richard Durbin (D-IL), respectively, would empower government officials to “negotiate with pharmaceutical manufactures with respect to the purchase price of covered part D drugs.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...